COMMUNIQUÉS West-GlobeNewswire

Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes
03/09/2019
Zealand Pharma company announcement – No. 29 / 2019 The dual acting GLP-1/glucagon peptide BI 456906 is a part of Boehringer Ingelheim’s pipeline portfolio in obesity and diabetes The Phase 2 trial for BI 456906 is [...]
Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine
03/09/2019
Worldwide agreement with Polpharma gives Sandoz commercialization rights to proposed biosimilar natalizumab for relapsing-remitting multiple sclerosis (RRMS) RRMS affects ~85% of MS patients and can create a substantial [...]
ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of Action, Supporting Its Potential to Increase Live Birth Rate Following Embryo Transfer in IVF
03/09/2019
Results show decreased uterine contractions, increased endometrial blood flow and gene expression relevant for uterine receptivity to implantation 4Q:19 Read-out confirmed for Phase 3 IMPLANT 4 trial of ObsEva’s novel [...]
argenx to Present at Morgan Stanley 17th Annual Global Healthcare Conference
03/09/2019
September 3, 2019 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]
Santhera Announces Financial Results for the First Half-Year 2019
03/09/2019
A conference call will be held today at 13:00 CEST, 12:00 BST, 07:00 EDT. Details are at the end of this statement. Pratteln, Switzerland, September 3, 2019 – Santhera Pharmaceuticals (SIX: SANN) reports first half-year [...]
Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.
03/09/2019
Basel, 3 September 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to [...]
Afya Limited Issues Guidance for 2nd Half of 2019
03/09/2019
On-track to Deliver 2019 Pro Forma Adjusted EBITDA above R$300 million NOVA LIMA, Brazil, Sept. 02, 2019 (GLOBE NEWSWIRE) -- Afya Limited, or Afya (Nasdaq: AFYA), today issued guidance for results for the second half of [...]
PROJECT HOPE GETS READY FOR HURRICANE DORIAN
02/09/2019
Project HOPE lines up medical team and health supplies to deploy in Category 5 storm’s aftermath Millwood, Virginia, Sept. 02, 2019 (GLOBE NEWSWIRE) -- As Hurricane Dorian makes its way to the United States, the global [...]
GENFIT: Board of Directors, Represented by Chairman Jean-François Mouney, Appoints Pascal Prigent as New CEO
02/09/2019
GENFIT: Board of Directors, Represented by Chairman Jean-François Mouney, Appoints Pascal Prigent as New CEO Lille (France), Cambridge (Massachusetts, United States), September 2, 2019 – GENFIT (Nasdaq and Euronext: [...]
GENFIT : Au nom du Conseil d’Administration, son Président Jean-François Mouney annonce la nomination de Pascal Prigent au poste de nouveau Directeur Général
02/09/2019
GENFIT : Au nom du Conseil d’Administration, son Président Jean-François Mouney annonce la nomination de Pascal Prigent au poste de nouveau Directeur Général Lille (France), Cambridge (Massachusetts, États-Unis), le 2 [...]
Össur hf: Transactions in relation to share buyback program
02/09/2019
Announcement no. 50/2019 2 September 2019 Transactions in relation to share buyback program On 14 May 2019, Össur hf. initiated a share buy-back program, see Company announcement no. 31/2019. The purpose of the share [...]
Information on total number of voting rights and shares composing the share capital as at August 31st, 2019
02/09/2019
Paris, September 2 nd , 2019 – 6.00PM CET - Pixium Vision (FR0011950641 - PIX), a bioelectronic company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent [...]
Information relative au nombre total de droits de vote et d’actions composant le capital social au 31 août 2019
02/09/2019
Paris, le 2 septembre 2019 – 18 :00 CET - Pixium Vision (FR0011950641 - PIX), société bioélectronique qui développe des systèmes de vision bionique innovants pour permettre aux patients ayant perdu la vue, de vivre de [...]
Number of voting rights as of August 31, 2019
02/09/2019
Nicox SA Société anonyme with a registered capital of € 29,910,120 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On September 2, 2019, MONTHLY PUBLICATION OF THE [...]
Nombre de droits de vote au 31 août 219
02/09/2019
Nicox SA Société anonyme au capital de 29 910 120 euros Siège social : DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 Le 2 septembre 2019, PUBLICATION MENSUELLE DU NOMBRE D’ [...]
Odiparcil development advances with recruitment of first patients in a new biomarker study in MPS VI children and adults
02/09/2019
Odiparcil development advances with recruitment of first patients in a new biomarker study in MPS VI children and adults Study conducted in the United-States aims to consolidate leucocyte GAG and skin GAG content [...]
Inventiva - Le développement d’odiparcil progresse avec le recrutement des premiers patients dans une nouvelle étude biomarqueur menée chez des adultes et enfants atteints de la MPS VI
02/09/2019
Le développement d’odiparcil progresse avec le recrutement des premiers patients dans une nouvelle étude biomarqueur menée chez des adultes et enfants atteints de la MPS VI L’étude menée aux Etats-Unis vise à étayer la [...]
IBA - Transparency notification
02/09/2019
Louvain-la-Neuve, Belgium, September 02, 2019, 17.35 Summary of the notification IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it [...]
IBA – PUBLICATION RELATIVE À UNE NOTIFICATION DE TRANSPARENCE
02/09/2019
Louvain-la-Neuve, Belgique, 2 septembre 2019, 17.35 Résumé de la notification IBA (Ion Beam Applications SA), le premier fournisseur mondial de solutions de protonthérapie pour le traitement du cancer, annonce devoir [...]

Pages